Mar. 2026
- March of 2026, Qurgen has completed SON-DP treatment for multiple late-stage solid tumor patients for over 18-months at low dose levels (2-4.5 mg/kg) and observed continue tumor shrinkage after 18-month SON-DP treatment without teratoma formation within these patients, indicating: 1. No drug resistant; 2. Safe and without teratoma formation which removes any safety concern of Qurgen’s cell-converting cancer therapy induced by SON-DP.